








# Improved Anti-Atopic Dermatitis Effect of *H. macrophylla* through the Generation of Hydrangenol by Microwave Processing

Youngseok Kim <sup>1,2†</sup>, Ha-Neul Ju <sup>1,2†</sup>, Pilju Choi <sup>1</sup>, Taejung Kim <sup>1</sup>,  
Young-Tae Park <sup>1</sup>, Dae-Hee Lee <sup>2\*</sup> and Jungyeob Ham <sup>1\*</sup>

<sup>1</sup>Natural Products Research Institute, Korea Institute of Science and Technology (KIST), Gangneung 25451, Republic of Korea

<sup>2</sup>Department of Marine Food Science and Technology, Gangneung-Wonju National University, Gangneung 25456, Republic of Korea

(Received November 01, 2021; Revised November 23, 2021; Accepted November 30, 2021)

**Abstract:** The compounds hydrangenol and hydrangenol 8-O-glucoside are abundant in *Hydrangea macrophylla*. This study investigated the effects of hydrangenol and hydrangenol 8-O-glucoside derived from *H. macrophylla* on atopic dermatitis (AD). Compared with hydrangenol 8-O-glucoside, hydrangenol resulted in more potent inhibition of interleukin 4 (IL-4) gene expression and  $\beta$ -hexosaminidase release, as well as more potent inhibition of the phosphorylation of signal transducer and activator of transcription 6 (STAT6). Ultra High-Performance Liquid Chromatography (UHPLC), the concentrations of hydrangenol were found to be lower than the concentration of hydrangenol 8-O-glucoside in *H. macrophylla* extracts. To increase the hydrangenol content of *H. macrophylla* extract, component conversion methods were studied. Conclusion, microwave processing was found to be the optimal method for deglycosylation.

**Keywords:** *Hydrangea macrophylla*; hydrangenol; hydrangenol 8-O-glucoside; atopic dermatitis; microwave irradiation. © 2021 ACG Publications. All rights reserved.

## 1. Introduction

Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by severe itching, dry skin, exudative eczema, and erythematous plaques [1]. The prevalence of AD is approximately 1%–3% in adults and 10%–20% in children. Compared with rural areas, AD is more prevalent in children in industrialized areas [2]. Atopic diseases are classified as either extrinsic or intrinsic. Compared with intrinsic AD, extrinsic AD is more prevalent as it arises from hypersensitivity reactions to substances, such as food, pollen, and house dust mites [3]. These reactions are mediated by immunoglobulin E (IgE). Extrinsic AD is characterized by elevated serum levels and mRNA expression of interleukin-4 (IL-4; an inflammatory cytokine produced by T helper 2 cells) [4,5]. Treatment with

\* Corresponding authors: E-Mail [neogene@gwnu.ac.kr](mailto:neogene@gwnu.ac.kr); Phone +82-33-640-2347 (D. Lee); [ham0606@kist.re.kr](mailto:ham0606@kist.re.kr); Phone +82-33-650-3501 (J. Ham)

† These two authors contributed equally to the work described in this study.

## Anti-atopic dermatitis effect of *H. macrophylla*

calcineurin inhibitors, such as cyclosporine A, can relieve atopic skin symptoms through the inhibition of IL-4 expression [6]. IL-4 is critical for the differentiation of naive CD4<sup>+</sup> T cells into TH2 cells.

Epidermal barrier defects play an essential role in AD pathogenesis by causing allergen penetration, water loss and infection [7]. In AD, elevation of Th2 cytokines may dysregulate barrier proteins [8]. A major pathway for IL-4 signaling in keratinocytes is the Jaks-STAT6 pathway. Th2 cytokine, IL-4, induces activation of the STAT6 signaling pathway through phosphorylation of Janus kinase (JAK)-1 and JAK3 [9].

Allergic diseases appear as hypersensitivity to allergic environmental substances in various target organs of the body (skin, nose, lungs, gastrointestinal tract, etc.), and include both IgE-mediated and non-IgE-mediated components [10]. When exposed to an allergen, B cells produce a number of antibodies called antigen-specific immunoglobulins (Ig) [11]. The allergic reaction is initiated when immunoglobulin E binds to specific receptors (FcRI) on mast cells and basophils [12]. This in turn leads to cell degranulation and release of mediators such as  $\beta$ -hexosaminidase, histamine, leukotriene, serotonin and platelet activating factor [13].

*Hydrangea macrophylla* is a deciduous shrub that belongs to the family saxifragaceae; it is abundant throughout Korea, China, Japan, and Indonesia, and it is commonly used in traditional herbal medicine [14]. In Japan, *H. macrophylla* flowers are dried and used as an antipyretic [15]. Furthermore, studies have reported the diverse pharmacological actions of hydrangeas, including antimalarial, anti-inflammatory, and antidiabetic effects [16–18]. Many studies have identified the most abundant compounds from *H. macrophylla* as hydrangenol and its derivative, hydrangenol 8-O-glucoside [19–22]. However, there has been no previous study of the effects of *H. macrophylla* on AD. Therefore, this study aimed to investigate the ability of the ethanolic extract of the aerial parts of *H. macrophylla* to inhibit the release of  $\beta$ -hexosaminidase from rat basophilic leukemia (RBL)-2H3 cells.

Microwave technology has been widely used to process dielectric materials such as food products currently, its usage is being expanded to include high-temperature material processing applications [23]. Microwave heating has competitive performance when compared with conventional methods as energy is introduced into the target material in a volumetric manner, which reduces the processing time and leads to a highly efficient process [24]. In this study, efforts were undertaken to apply this technology to the isolation of hydrangenol, which is the most abundant phytochemical in *H. macrophylla*, and to investigate its anti-AD effects.

## 2. Materials and Methods

### 2.1. Plant material, Extraction, and Isolation

Whole *H. macrophylla* was purchased from a local Herbmaul in Cheongju and it was identified by a taxonomist (Nakdonggang National Institute of Biological Resources, Dr. Jeong-Ki Hong). A voucher specimen of the species was deposited at Natural Product Research Center of Korea Institute of Science and Technology Gangneung (NP-F-195). The dried aerial parts of *H. macrophylla* (50 g) were extracted twice in 2 L of ethanol and then evaporated under reduced pressure to yield the extract (14 g).

The extract was resuspended in 1 L of distilled water and successively partitioned with 1 L of hexane and 1 L of ethyl acetate, which yielded 2.0 g and 0.9 g of residue, respectively. To identify the active ingredients that were responsible for the anti-AD activity, the activity of each fraction was evaluated in RBL2H3 and HaCaT cells. The active ethyl acetate-soluble fraction (0.9 g) was purified by semi-preparative HPLC (Gilson Inc, Middleton, WI, USA) using an acetonitrile/water mobile phase (20/80 to 60/40, v/v) and a Phenomenex Luna C18 column (250 × 10 mm, 5  $\mu$ m, Phenomenex, Torrance, CA, USA) at a flow rate of 4 mL·min<sup>-1</sup> to obtain hydrangenol 8-O-glucoside (123.8 mg, purity 97.1%) and hydrangenol (47.0 mg, purity 98.6%). The chemical structures of the two compounds were determined through comparison with previously reported references [25,26].

## 2.2. Analysis

The *H. macrophylla* extract was dissolved in methanol and then filtered through a 0.45- $\mu\text{m}$  polytetrafluoroethylene (PTFE) membrane filter. An analytical reversed-phase Shimadzu Nexera X2 Ultra High-Performance Liquid Chromatography (UHPLC, Shimadzu, Kyoto, Japan) system comprising of a solvent degassing unit (DGU-20A, Shimadzu), binary pump (LC-30AD, Shimadzu), autosampler (SIL-30AC, Shimadzu), system controller unit (CBM-20A, Shimadzu), photodiode array detector (SPD-M20A, Shimadzu), and column oven unit (CTO-20AC, Shimadzu) was used for qualitative and/or quantitative analyses. Electrospray ionization (ESI)-mass spectrometry (MS) was performed using a Shimadzu LCMS-2020 system for qualitative analysis. A Phenomenex Luna Omega polar C18 column (150  $\times$  2.1 mm, 1.6  $\mu\text{m}$ , Phenomenex, Torrance, CA, USA) was used. The mobile phase consisted of binary gradients of solvents A (water) and B (acetonitrile). The flow rate was set to 0.3 mL $\cdot\text{min}^{-1}$  and the solvent gradient was as follows: 0 min, 10% B; 20 min, 60% B; 26 min, 10% B. The detection wavelength was 200 nm and the injection volume was 3  $\mu\text{L}$ . The analysis was performed three times.

## 2.3. Microwave Irradiation

The ethyl acetate fraction of *H. macrophylla* was processed using a microwave. For each 1 mg of dry extract, 1 mL of 50% EtOH was added into a 10 mL microwave reactor container (model no.: 908005) manufactured by CEM (Matthews, NC, USA). The dry extract was exposed to microwave irradiation in sealed containers at temperatures of 80°C, 90°C, 100°C, 110°C, 120°C, 130°C, and 140°C at a power of 150 W (a frequency of 2450 MHz) for 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, and 120 min. The microwave-irradiated dry extracts were freeze dried to obtain the microwave-irradiated products. The microwave irradiation was conducted at a pressure of 20 atm.

## 2.4. Cells

RBL-2H3, which is a rat basophilic leukemia mast cell line (Korea Cell Line Bank, Seoul, Korea), was grown in Dulbecco Modified Eagle Medium (DMEM, GenDEPOT, TX, USA) supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific, MA, USA) 2 mM glutamine, 100 U/mL penicillin, and 100  $\mu\text{g}/\text{mL}$  streptomycin in a humidified 5%  $\text{CO}_2/\text{air}$  atmosphere at 37°C [27]. Human keratinocyte (HaCat) cells (German Cancer Research Center, Heidelberg, Germany) were grown in DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin, and 100  $\mu\text{g}/\text{mL}$  streptomycin in a humidified 5%  $\text{CO}_2/\text{air}$  atmosphere at 37°C.

## 2.5. Expression of IL-4 from RBL-2H3 Cells

RBL-2H3 cells were seeded in DMEM (with 10% FBS) containing either dimethyl sulfoxide (DMSO), *H. macrophylla* extract (10  $\mu\text{M}$ ), hydrangenol (10  $\mu\text{M}$ ), or hydrangenol 8-O-glucoside (10  $\mu\text{M}$ ) for 1 h. Then, treatment with phorbol 12-myristate 13-acetate (PMA, sigma aldrich, MA, USA)/ionomycin (PI, sigma aldrich, MA, USA) was applied for 8 h to induce an AD-like condition. The cells were then harvested to synthesize complementary deoxyribonucleic acid (cDNA), after which real-time quantitative polymerase chain reaction (qPCR) was used to measure IL-4 mRNA expression. Total RNA was isolated from cells using TRIzol Reagent (Thermo Fisher Scientific, MA, USA) in accordance with the manufacturer's instructions. The accumulation of PCR products was observed directly by checking for increases in the reporter dye. At each time point, cytokine expression levels in the treated cells were compared with those in controls using the comparative cycle threshold (Ct) method. The TaqMan probes and primers used were Rn01456866\_m1 for IL-4 and Hs03003631\_g1 for the reference gene, 18s RNA; all probes and primers were obtained from Life Technologies, Carlsbad, CA, USA.

## Anti-atopic dermatitis effect of *H. macrophylla*

### 2.6. $\beta$ -Hexosaminidase Release Assay

RBL-2H3 cells were treated overnight with anti-dinitrophenyl (anti-DNP) IgE (sigma aldrich, MA, USA), rinsed with Siraganian buffer (119 mM NaCl, 5 mM KCl, 1 mM CaCl<sub>2</sub>, 0.4 mM MgCl<sub>2</sub>, 25 mM PIPES, 5.6 mM glucose, 0.1% bovine serum albumin, pH 7.2, biosolution, Seoul, Korea) and then incubated in buffer for 10 min. The cells were then treated with DMSO or separately with each of the isolates of *H. macrophylla* extract, hydrangenol, or hydrangenol 8-O-glucoside (10, 30  $\mu$ M) for 20 min, and then sensitized with DNP-bovine serum albumin (BSA, sigma aldrich, MA, USA) antigen (10  $\mu$ g/mL) for 30 min to induce degranulation. The supernatant was then transferred to a 96-well plate and incubated with 1 mM 4-nitrophenyl-N-acetyl- $\beta$ -D-glucosaminide as a substrate in 0.1 M citrate buffer for 1 h at 37°C. The absorbance at 405 nm was measured using a microplate reader [28].

### 2.7. Expression of STAT6 in HaCaT Cells

HaCaT cells were seeded in DMEM (with 10% FBS) containing either dimethyl sulfoxide (DMSO), *H. macrophylla* extract (10  $\mu$ M), hydrangenol (10  $\mu$ M), or hydrangenol 8-O-glucoside (10  $\mu$ M) for 1 h and then treated with human recombinant IL-4 protein (hIL-4; R&D systems, MN, USA) for 30 min. To analyze the protein expression, HaCaT cells were harvested and homogenized at 4°C in lysis buffer. After centrifugation, the cell debris was discarded, and the protein concentration was determined using the bicinchoninic acid (BCA) assay. Then, 20 mg of protein was separated using 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) gel and the separated proteins were transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA).

The membranes were blocked with 5% skimmed milk at room temperature for 1 h and then incubated with primary antibodies. For western blotting, anti-STAT6 and anti-phospho-STAT6 (Cell Signaling Technology, Beverly, MA, USA) were used as the primary antibodies. Anti-rabbit IgG-horseradish peroxidase (HRP) and anti-mouse IgG-HRP were purchased from Cell Signaling Technology and used as secondary antibodies. The protein expression signal was detected with Pierce<sup>®</sup> ECL Western Blotting substrate (Thermo Fisher Scientific, MA, USA). The immunoreactive bands were visualized using an enhanced Amersham ImageQuant 800 (Cytiva, Marlborough, MA, USA). An anti- $\beta$ -actin antibody was used to monitor protein loading in each lane. The densitometric analysis was performed using ImageJ software.


### 2.8. Statistical Analysis

All quantitative data for this study were obtained through at least two independent experiments. *In vitro* data are presented as the mean  $\pm$  standard deviation (SD). Statistical analyses were performed using one-way analysis of variance (ANOVA) and Tukey's multiple comparison post-hoc analysis.

## 3. Results and Discussion

### 3.1. Conversion of Hydrangenol 8-O-glucoside into Hydrangenol using Microwave Irradiation


The chromatograms for hydrangenol and hydrangenol 8-O-glucoside derived from the prepared *H. macrophylla* extracts are shown in Figure 1. Then, we investigated the effect of processing temperature and reaction time on the content of hydrangenol in the *H. macrophylla* extract. When microwave irradiation was performed at temperature between 80°C and 110°C and a reaction time between 10 and 90 min, the content of the major constituent (hydrangenol 8-O-glucoside) gradually decreased, whereas that of the minor constituent (hydrangenol) increased by deglycosylation. The generated amounts of hydrangenol reached a maximum after microwave irradiation at 90°C for 90 min (see Supporting Information for details). In addition, thermal decarboxylation of the dihydroisocoumarin skeleton of hydrangenol occurred after microwave irradiation at temperatures above 120°C.



**Figure 1.** Effect of microwave irradiation on the conversion of hydrangenol 8-O-glucoside to hydrangenol. (a) Ultra high-performance liquid chromatography (UHPLC) chromatograms of *H. macrophylla* and the microwave-irradiated extracts. (b) Chemical structures of the main compounds in *H. macrophylla* and the microwave-irradiated extracts.


### 3.2. Effects of *H. macrophylla* Extracts on IL-4 Expression in RBL-2H3 Cells

IL-4 mRNA expression was significantly increased by PI treatment for 8 h (6.7-fold versus vehicle controls). As shown in Figure 2, IL-4 mRNA expression was lower in cells that were pre-treated with *H. macrophylla* EA extract and hydrangenol and hydrangenol 8-O-glucoside and then stimulated with PI, compared with the PI-treated controls. Both compounds exhibited concentration-dependent inhibitory effects on IL-4 expression, with hydrangenol showing a better overall effect.




Anti-atopic dermatitis effect of *H. macrophylla*

(b)



(c)




**Figure 2.** Anti-inflammatory effects of *H. macrophylla* extract and fraction in rat basophilic leukemia cell line (RBL-2H3) cells. (a) Effects of *H. macrophylla* extract and fraction on interleukin 4 (IL-4) mRNA expression in PMA/ionomycin (PI)-mediated RBL-2H3 cells. (b) Effects of *H. macrophylla* EA fraction on interleukin 4 (IL-4) mRNA expression in PMA/ionomycin (PI)-sensitized RBL-2H3 cells. (c) Effects of hydrangenol and hydrangenol 8-O-glucoside on interleukin 4 (IL-4) mRNA expression in PMA/ionomycin (PI)-sensitized RBL-2H3 cells. Results are expressed as the means  $\pm$  SD of two independent experiments. #  $p < 0.05$  vs. vehicle control; \*  $p < 0.05$  vs. PI. #E : EtOH extract, He : Hexane fraction, EA : Ethyl acetate fraction, Bu : Butanol fraction, H : Water fraction


### 3.3. Effects of *H. macrophylla* Extracts on $\beta$ -Hexosaminidase Release in RBL-2H3 Cells

DNP-BSA was previously shown to increase  $\beta$ -hexosaminidase release in IgE-sensitized RBL-2H3 cells [29]. As shown in Figure 3, the release of  $\beta$ -hexosaminidase was lower in cells pretreated with *H. macrophylla* EA extract and hydrangenol and hydrangenol 8-O-glucoside than in the control. In particular, hydrangenol markedly inhibited  $\beta$ -hexosaminidase release in RBL-2H3 cells. DNP-BSA-IgE alone caused significant  $\beta$ -hexosaminidase release (3.5-fold versus untreated controls), but treatment with 30  $\mu$ M hydrangenol reduced this increase by 42%.

(a)




(b)



**Figure 3.** Anti-inflammatory effects of *H. macrophylla* extract and fraction in rat basophilic leukemia cell line (RBL-2H3) cells. (a) Effects of *H. macrophylla* extract on  $\beta$ -hexosaminidase release from immunoglobulin E (IgE)-sensitized RBL-2H3 cells. (b) Effects of hydrangenol and hydrangenol 8-O-glucoside on  $\beta$ -hexosaminidase release from immunoglobulin E (IgE)-sensitized RBL-2H3 cells. Results are expressed as the means  $\pm$  SD of two independent experiments. #  $p < 0.05$  vs. vehicle control; \*  $p < 0.05$  vs. DNP-BSA  
 #DNP-BSA : Dinitrophenyl bovine serum albumin

### 3.4. Effects of *H. macrophylla* Extracts on STAT6 Phosphorylation in HaCaT Cells

STAT6 phosphorylation was significantly increased by recombinant hIL-4 treatment for 15 min (6.7-fold versus the vehicle control). As shown in Figure 4, STAT6 phosphorylation was lower in cells that were pre-treated with *H. macrophylla* EA extract and hydrangenol and hydrangenol 8-O-glucoside and then stimulated with recombinant hIL4 compared with the controls treated with recombinant hIL4. Hydrangenol had a stronger inhibitory effect on STAT6 phosphorylation than hydrangenol 8-O-glucoside.

Anti-atopic dermatitis effect of *H. macrophylla*

**Figure 4.** STAT6 phosphorylation of *H. macrophylla* extract and fraction in Human Keratinocyte (HaCaT) cells. (a) Effects of *H. macrophylla* extract on STAT6 phosphorylation from human recombinant IL-4-mediated HaCaT cells. (b) Effects of hydrangenol and hydrangenol 8-O-glucoside on STAT6 phosphorylation from human recombinant IL-4-mediated HaCaT cells. Results are expressed as the means  $\pm$  SD of two independent experiments. #  $p < 0.05$  vs. vehicle control; \*  $p < 0.05$  vs. IL-4.

#STAT6 : Signal transducer and activator of transcription 6, H : Hydrangenol, HG : Hydrangenol 8-O-glucoside

In conclusion, this study aimed to investigate the two constituents of *H. macrophylla* extract with effective anti-atopic dermatitis. The results showed that the minor constituent of *H. macrophylla* extract, hydrangenol, exhibited significant activity, indicating that hydrangenol was the active constituent of *H. macrophylla* that exerted immunosuppressive effects on inflammation. It suppressed the expression of IL-4, a Th2 cytokine, suppressed cell degranulation, and suppressed the expression of STAT6, a major pathway of IL-4 signaling in keratinocytes. This can alleviate the imbalance of Th2 cytokine, a major cause of atopy, and increase the function of the skin barrier protein. Furthermore, several methods to increase the hydrangenol content of *H. macrophylla* extracts were investigated, and microwave irradiation was found to be the optimal method for deglycosylation. This may be useful for the prevention and amelioration of AD, and also established a basis for the future utilization of hydrangenol.

## Acknowledgments

We thank Dr. Jeong-Ki Hong (Nakdonggang National Institute of Biological Resources) for identifying the *H. macrophylla*. This work was supported by the industrial infrastructure program for fundamental technologies, which is funded by the Ministry of Trade, Industry & Energy (20000105) and the R&D Grant (Development of natural products for healthcare healing industry) from Gangneung Science & Industry Promotion Agency and research funds for newly appointed professors of Gangneung-Wonju National University in 2019.



## Supporting Information

Supporting information accompanies this paper on <http://www.acgpubs.org/journal/records-of-natural-products>

### ORCID

Youngseok Kim: [0000-0002-1599-3258](https://orcid.org/0000-0002-1599-3258)

Ha-Neul Ju: [0000-0002-3405-8679](https://orcid.org/0000-0002-3405-8679)

Pilju Choi: [0000-0003-2838-941X](https://orcid.org/0000-0003-2838-941X)

Taejung Kim: [0000-0002-9449-4763](https://orcid.org/0000-0002-9449-4763)

Young-Tae Park: [0000-0003-1787-1577](https://orcid.org/0000-0003-1787-1577)

Dae-Hee Lee: [0000-0002-8960-1632](https://orcid.org/0000-0002-8960-1632)

Jungyeob Ham: [0000-0003-3046-9267](https://orcid.org/0000-0003-3046-9267)

## References

- [1] D.Y. Leung, M. Boguniewicz, M.D. Howell, I. Nomura and Q.A. Hamid (2004). New insights into atopic dermatitis, *J. Clin. Invest.* **113**, 651-657.
- [2] H.C. Williams (2010). Atopic dermatitis, *N. Engl. J. Med.* **352**, 2314-2324.
- [3] Y. Tokura (2010). Extrinsic and intrinsic types of atopic dermatitis, *J. Dermatol. Sci.* **58**, 1-7.
- [4] H. Renz, K. Jujo, K.L. Bradley, J. Domenico, E.W. Gelfand and D.Y. Leung (1992). Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma, *J. Invest. Dermatol.* **99**, 403-408.
- [5] J. Yang, W.S. Choi, K.J. Kim, C.D. Eom and M.J. Park (2021). Investigation of active anti-inflammatory constituents of essential oil from *Pinus koraiensis* (Sieb. et Zucc.) wood in LPS-stimulated RBL-2H3 cells, *Biomolecules* **11**, 817.
- [6] E.L. Simpson (2010). Atopic dermatitis: a review of topical treatment options, *Curr. Med. Res. Opin.* **26**, 633-640.
- [7] T. Miyagaki, and M. Sugaya (2015). Recent advances in atopic dermatitis and psoriasis: genetic background, barrier function, and therapeutic targets, *J. Dermatol. Sci.* **78**, 89-94.
- [8] S. Hönzke, L. Wallmeyer, A. Ostrowski, M. Radbruch, L. Mundhenk, M. Schäfer-Korting and S. Hedtrich. (2016). Influence of Th2 cytokines on the cornified envelope, tight junction proteins, and  $\beta$ -defensins in filaggrin-deficient skin equivalents, *J. Invest. Dermatol.* **136**, 631-639.
- [9] D.W. Choi, S.Y. Jung, D.H. Shon and H.S. Shin. (2020). Piperine Ameliorates trimellitic anhydride-induced atopic dermatitis-like symptoms by suppressing Th2-mediated immune responses via inhibition of STAT6 phosphorylation, *Molecules* **25**, 2186.
- [10] H. Metzger, G. Alcaraz, R. Hohman, J. P. Kinet, V. Pribluda and R. Quarto (1986). The receptor with high affinity for immunoglobulin E, *Ann. Rev. Immunol.* **4**, 419-470.
- [11] I. B. Haydik and W. Ma (1988). Basophil Histamine Release, *Clin. Rev. Allergy* **6**, 141-162.
- [12] K. Ishizaka, T. Ishizaka and E. H. Lee (1970). Biologic function of the Fc fragments of E myeloma protein, *Immunochemistry* **7**, 687-694.
- [13] T. Ishizaka, D. H. Conrad, E.S. Schulman, A. R. Sterk and K. Ishizaka (1983). Biochemical analysis of initial triggering events of IgE-mediated histamine release from human lung mast cells, *The J. Immunol.* **130**, 2357-2362.
- [14] S.M. Reed, K.D. Jones and T.A. Rinehart (2008). Production and characterization of intergeneric hybrids between *Dichroa febrifuga* and *Hydrangea macrophylla*, *J. Am. Soc. Hort. Sci.* **133**, 84-91.
- [15] J. Liu, S. Nakamura, Y. Zhuang, M. Yoshikawa, G.M.E. Hussein, K. Matsuo and H. Matsuda (2013). Medicinal Flowers. XXXX.<sup>1)</sup> Structures of dihydroisocoumarin glycosides and inhibitory effects on aldose reductase from the flowers of *Hydrangea macrophylla* var. *thunbergii*, *Chem. Pharm. Bull.* **61**, 655-661.
- [16] H. Zhang, H. Matsuda, C. Yamashita, S. Nakamura and M. Yoshikawa (2009). Hydrangeic acid from the processed leaves of *Hydrangea macrophylla* var. *thunbergii* as a new type of anti-diabetic compound, *Eur. J. Pharmacol.* **606**, 255-261.

Anti-atopic dermatitis effect of *H. macrophylla*

- [17] H. Matsuda, Q. Wang, K. Matsuhira, S. Nakamura, D. Yuan and M. Yoshikawa (2008). Inhibitory effects of thunberginols A and B isolated from *Hydrangeae dulcis* Folium on mRNA expression of cytokines and on activation of activator protein-1 in RBL-2H3 cells, *Phytomedicine* **15**, 177-184.
- [18] K. Kamei, H. Matsuoka, S. Furuhashi, R. Fujisaki, T. Kawakami, S. Mogi, H. Yoshihara, N. Aoki, A. Ishii and T. Shibuya (2000). Anti-malarial activity of leaf-extract of *Hydrangea macrophylla*, a common Japanese plant, *Acta. Medica. Okayama*. **54**, 227-232.
- [19] H. Zhang, H. Matsuda, A. Kumahara, Y. Ito, S. Nakamura and M. Yoshikawa (2007). New type of anti-diabetic compounds from the processed leaves of *Hydrangea macrophylla* var. *thunbergii* (*Hydrangeae dulcis* Folium), *Bioorg. Med. Chem. Lett.* **17**, 4972-4976.
- [20] Y.J. Jo, J.S. Hyun, C.Y. Kim and N.H. Lee (2020). Anti-oxidative and anti-inflammatory constituents from the extracts of *Hydrangea macrophylla* flowers, *J. Korean. App. Sci. Tech.* **37**, 1356-1365.
- [21] J.S. Shin, H.S. Han, S.B. Lee, D. Myung, K. Lee, S.H. Lee, H.J. Kim and K.T. Lee (2019). Chemical constituents from leaves of *Hydrangea serrata* and their anti-photoaging effects on UVB-irradiated human fibroblasts, *Biol. Pharm. Bull.* **42**, 424-431.
- [22] S. Asen, H.M. Cathey and N.W. Stuart (1960). Enhancement of gibberellin growth-promoting activity by hydrangenol isolated from leaves of *Hydrangea macrophylla*, *Plant Physiol.* **35**, 816.
- [23] J. Zhu, A.V. Kuznetsov and K.P. Sandeep (2007). Numerical simulation of forced convection in a duct subjected to microwave heating, *Int. J. Heat. Mass. Transf.* **43**, 255-264.
- [24] G. Cuccurullo, L. Giordano and G. Viccione (2013). An analytical approximation for continuous flow microwave heating of liquids, *Adv. Mech. Eng.* **5**, 929236.
- [25] D. Myung, H.S. Han, J.S. Shin, J.Y. Park, H.J. Hwang, H.J. Kim, H.S. Ahn, S.H. Lee and K.T. Lee (2019). Hydrangenol isolated from the leaves of *Hydrangea serrata* attenuates wrinkle formation and repairs skin moisture in UVB-irradiated hairless mice, *Nutrients* **11**, 2354
- [26] H. Matsuda, H. Simoda, J. Yamahara and M. Yoshikawa (1999). Effects of phylloolulcin, hydrangenol, and their 8-O-glucosides, and thunberginols A and F from *Hydrangea macrophylla* SERINGE var. *thunbergii* MAKINO on passive cutaneous anaphylaxis reaction in rats, *Biol. Pharm. Bull.* **22**, 870-872.
- [27] S. Lee, H. Jegal, S.K. Bong, K.N. Yoon, N.J. Park, M.S. Shin, M.H. Yang, Y.K. Kim and S.N. Kim (2020). Anti-atopic effect of acorn shell extract on atopic dermatitis-like lesions in mice and its active phytochemicals, *Biomolecules* **10**, 57.
- [28] T.Y. Kim, N.J. Park, J. Jegal, S. Choi, S.W. Lee, J. Hang, S.N. Kim and M.H. Yang (2019). Chamaejasmine isolated from *Wikstroemia dolichantha* Diels suppresses 2,4-dinitrofluoro-benzene-induced atopic dermatitis in SKH-1 hairless mice, *Biomolecules* **9**, 697.
- [29] B.C. Liao, R.C.W. Hou, J.S. Wang and K.C.G. Jeng (2006). Enhancement of the release of inflammatory mediators by substance P in rat basophilic leukemia RBL-2H3 cells, *J. Biomed. Sci.* **13**, 613-619.

**A C G**  
publications

© 2021 ACG Publications